Dimerix Limited (ASX: DXB)
Sector: Health Care
Market cap: A$126M (as of 2 Nov 2026)
is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using our innovative
Data as of 2 Nov 2026.
Recent capital raises
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 28 Aug 2025 | MR PETER FLETCHER MEURS | Entry | ?% → 6.67% | Filing ↗ |
| 20 May 2025 | Skiptan Pty Ltd ATF P & M Meurs Family Trust | Increase | 13.800% → 15.080% | Filing ↗ |
| 29 Aug 2024 | MR PETER FLETCHER MEURS | Entry | ?% → 6.46% | Filing ↗ |
| 21 Mar 2024 | Skiptan Pty Ltd ATF P & M Meurs Family Trust | Decrease | 15.090% → 13.800% | Filing ↗ |
| 14 Mar 2024 | MR PETER FLETCHER MEURS | Decrease | 16.740% → 15.090% | Filing ↗ |
Director trades — on-market
| Date | Director | Trade | Source |
|---|---|---|---|
| 27 Mar 2024 | Dr Nina Webster | Bought 33,000 ordinary shares | Filing ↗ |
Cash and runway
| Metric | Value | As of | Source |
|---|---|---|---|
| Cash | A$35M | 30 Sept 2026 | Filing ↗ |
Ask about DXB in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has DXB raised money in the last year, and at what discount?
- What was DXB's latest cash position and runway?
Loading DXB…